Please note that the ABCD DTN-UK Meeting 2023 programme is subject to change

This joint guidance from the PCDS and ABCD aims to support clinicians in selecting alternative glucose-lowering therapies when GLP-1 RAs are unavailable during this period of national shortage.

The Department for Health and Social Care (DHSC) have issued a National Patient Safety Alert regarding the shortage of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). 

A summary of the alert is provided below: 

There are very limited, intermittent supplies of all GLP-1 RAs. Supplies are not expected to stabilise to meet full market demand until at least mid-2024. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications.

Medicine Supply Notification

GLP-1 receptor agonists* used in the management of type 2 diabetes

MSN/2023/061

Tier 3 – high impact**

Date of issue: 27/06/2023

Link: Medicines Supply Tool

The Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD) are very concerned about the ongoing national shortage affecting the availability of GLP-1 receptor analogues (GLP-1 RAs). This is very difficult for people with diabetes who are unable to access their GLP-1 RA medication, and for their clinicians who are unable to provide the treatment they feel is necessary.

Please find below, in the File(s) section of this page, the presentations featured at the DTN-UK Team Education Day 2023.

The 2023 Endocrinology & Diabetes Specialty Certificate Examination is proceeding as scheduled on 14th June 2023.